EP3291834A1 - Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies - Google Patents
Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobuliesInfo
- Publication number
- EP3291834A1 EP3291834A1 EP16725051.3A EP16725051A EP3291834A1 EP 3291834 A1 EP3291834 A1 EP 3291834A1 EP 16725051 A EP16725051 A EP 16725051A EP 3291834 A1 EP3291834 A1 EP 3291834A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunoglobulins
- polyclonal human
- human immunoglobulins
- composition
- polyclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Definitions
- the present invention is in the field of therapeutic concentrates of polyclonal immunoglobulins. It relates to a composition highly enriched in anti-A and / or anti-B polyclonal immunoglobulins, for its use in the treatment of autoimmune diseases (in particular idiopathic thrombocytopenic purpura), and / or in the treatment of polyglobulia.
- autoimmune diseases in particular idiopathic thrombocytopenic purpura
- polyglobulia in particular idiopathic thrombocytopenic purpura
- Normal human immunoglobulins are used in the treatment of more and more pathologies. They are used as substitution therapy in primary (congenital deficiency) or secondary (chronic lymphocytic leukemia, myeloma, infections after bone marrow transplant, recurrent bacterial infections in HIV-infected 'antibody.
- ITP idiopathic thrombocytopenic purpura
- NMM multifocal motor neuropathy
- IPDC chronic inflammatory demyelinating polyradiculoneuritis
- IVIG normal human immunoglobulin intravenously
- plasma fractionators have developed methods to eliminate anti-A and anti-B immunoglobulins. of their normal human immunoglobulin concentrates.
- WO01 / 27623 and WO2007 / 077365 describe the use of different affinity chromatography supports specifically binding to anti-A and anti-B immunoglobulins to eliminate anti-A and anti-B immunoglobulins from biological compositions, especially from normal human immunoglobulin concentrates.
- the non-adsorbed fraction not comprising anti-A and anti-B immunoglobulins is recovered by percolation for further processing and conditioning.
- the anti-A anti-A affinity chromatography column is then regenerated by a double wash: a first acid wash, followed by a second basic wash. To date, the two products from each of the two washes are eliminated.
- the anti-A and anti-B immunoglobulin fraction adsorbed during the affinity chromatography step therefore corresponds to a lost fraction.
- the inventors have discovered that the currently eliminated fraction, strongly enriched in anti-A and anti-B immunoglobulins, may be used in the treatment of autoimmune diseases (in particular idiopathic thrombocytopenic purpura (ITP)). , and / or in the treatment of polyglobulia.
- autoimmune diseases in particular idiopathic thrombocytopenic purpura (ITP)
- ITP idiopathic thrombocytopenic purpura
- compositions of anti-A and / or anti-B immunoglobulins in the treatment of autoimmune diseases and in particular of ITP is that these anti-A and / or anti-B immunoglobulins, administered to a blood group patient A, B or AB with an autoimmune disease, will compete with the endogenous phenomena.
- the anti-A and / or anti-B immunoglobulins would make it possible to induce destruction of the patient's red blood cells by a phagocytosis phenomenon of a fraction of red blood cells and thus indirectly protect the platelets from their destruction via macrophages.
- the Fc receptors of macrophages are saturated directly by red blood cells coated with anti-A and / or anti-B immunoglobulin, limiting and / or thus preventing the destruction of platelets.
- a second possible mechanism is the consumption of complement proteins by anti-A and / or anti-B immunoglobulin-coated red cells, reducing the complement-dependent activity of pathogenic autoantibodies.
- This mechanism applies to all autoimmune pathologies for which the role of complement is deleterious for the patient, for example optical neuromyelitis (anti-AQP4) and multiple sclerosis (anti-myelin / axon).
- a third possible mechanism is an anti-inflammatory action of erythrocytes coated with anti-A and / or anti-B immunoglobulins, due to the inhibition induced by their phagocytosis of the pro-inflammatory cytokine secretion by the activated macrophages.
- This mechanism applies to all autoimmune pathologies for which the effector cells expressing Fc receptors, in particular CD16, are activated and maintain a pathogenic inflammatory state in the patient, which is observed in a large number of autoimmune pathologies. immune.
- An immunomodulation phenomenon is also possible. Indeed, a fourth possible mechanism is based on the immunomodulatory action of red blood cells coated with anti-A and / or anti-B immunoglobulins, which by limiting the cell destruction, allow the induction of a negative signal and thus a decrease of cross-link secretion of autoantibodies between BCR and FcgRIIb of B cell via autoantibody and antigen expressed on the surface of the target cell.
- This mechanism applies to all autoimmune pathologies for which a pathogenic autoantibody is demonstrated such as ITP, insulin autoimmune syndrome (IAS) or Hirata disease (anti-insulin), optical neuromyelitis (anti-AQP4) , Grave's disease, pemphigus, multiple sclerosis (anti-myelin / axon), Sydenham chorea (anti-neuronal protein), Sjögren, Pemphigus vulgaris (anti-desmoglein 3).
- a fifth mechanism is the induction of anti-inflammatory cytokines such as IL1-RA by immune system cells, epithelial cells and adipocytes induced by erythrocytes coated with anti-A and / or anti-B immunoglobulins.
- This mechanism is particularly applicable in inflammatory diseases such as rheumatoid arthritis or for example Muckle-Wells syndrome and Schnitzler syndrome.
- the anti-A and / or anti-B immunoglobulins will directly bind to the red blood cells of patients with blood group A, B or AB and thus induce the lysis of supernumerary red blood cells.
- the present invention thus relates to a composition
- a composition comprising polyclonal human immunoglobulins, characterized in that at least 80% by weight of the polyclonal human immunoglobulins present in the composition are polyclonal human anti-A and / or anti-human immunoglobulins.
- B for its use as a medicine.
- the invention also relates to a composition
- a composition comprising polyclonal human immunoglobulins, characterized in that at least 80% by weight of the polyclonal human immunoglobulins present in the composition are polyclonal human anti-A and / or anti-B immunoglobulins for its use.
- the polyclonal human immunoglobulins represent at least 85% by weight of the total proteins of the composition.
- the invention also relates to the use of a composition comprising polyclonal human immunoglobulins, characterized in that at least 80% by weight of the polyclonal human immunoglobulins present in the composition are polyclonal human anti-A and / or anti-human immunoglobulins.
- B for the preparation of a medicament, in particular for the treatment of autoimmune diseases (especially idiopathic thrombocytopenic purpura (ITP)) and / or the treatment of polyglobulia.
- the invention also relates to a method of treating autoimmune diseases (especially idiopathic thrombocytopenic purpura (ITP)) and / or polyglobuli in a subject in need, comprising administering to said subject an effective amount of a composition comprising polyclonal human immunoglobulins, characterized in that at least 80% by weight of the polyclonal human immunoglobulins present in the composition are anti-A and / or anti-B polyclonal human immunoglobulins.
- autoimmune diseases especially idiopathic thrombocytopenic purpura (ITP)
- ITP idiopathic thrombocytopenic purpura
- compositions are intended for patients of blood group A, B or AB.
- the composition comprises both anti-A polyclonal human immunoglobulins and anti-B polyclonal human immunoglobulins, and the ratio by weight polyclonal human anti-A immunoglobulins on anti-B polyclonal human immunoglobulins ( anti-A / anti-B) is between 1/10 and 10/1.
- the composition is advantageously intended for patients of blood group A, B or AB. DESCRIPTION OF THE FIGURES
- FIG. 1 Schematic of the murine model used to test the therapeutic efficacy of anti-A and / or anti-B polyclonal immunoglobulins in the treatment of idiopathic thrombocytopenic purpura (ITP).
- ITP idiopathic thrombocytopenic purpura
- the arrows above the timeline correspond to blood collections.
- the small solid arrows below the time line correspond to the injections of anti-CD41 antibodies (1 g / 20 g of weight for each mouse, intraperitoneally).
- the long dashed arrows below the time line correspond to the injection of human red blood cells AB + (400 ⁇ l, intravenous), or the injection of IVIG (2 g / kg, intraperitoneally) or anti-A / anti-B (7.5 mg / kg, intraperitoneally).
- FIG. 1 Graphical presentation of the results obtained, reported as a percentage of day 1, on the murine model used to test the therapeutic efficacy of anti-A and / or anti-B polyclonal immunoglobulins in the treatment of idiopathic thrombocytopenic purpura (ITP).
- Gr1 group 1
- Gr2 group 2
- Gr3 group 3
- Gr4 group 4
- Gr5 group 5.
- the inventors have discovered that the currently eliminated fraction, strongly enriched in anti-A and anti-B immunoglobulins, may be used in the treatment of autoimmune diseases (in particular idiopathic thrombocytopenic purpura (ITP)), and / or in the treatment of polycythemia.
- autoimmune diseases in particular idiopathic thrombocytopenic purpura (ITP)
- ITP idiopathic thrombocytopenic purpura
- compositions of anti-A and / or anti-B immunoglobulins in the treatment of autoimmune diseases and in particular of ITP is that these anti-A and / or anti-B immunoglobulins administered to the group patient blood A, B or AB presenting an autoimmune disease will compete with endogenous phenomena.
- the anti-A and / or anti-B immunoglobulins would make it possible to induce destruction of the patient's red blood cells and thus indirectly protect the platelets from their destruction via the macrophages. Indeed, the Fc receptors of macrophages are saturated directly by red blood cells coated with anti-A and / or anti-B immunoglobulin, thus preventing the destruction of platelets.
- a second possible mechanism is the consumption of complement proteins by anti-A and / or anti-B immunoglobulin-coated red cells, reducing the complement-dependent activity of pathogenic autoantibodies.
- This mechanism applies to all autoimmune pathologies for which the role of the complement is deleterious for the patient such as optical neuromyelitis (anti-AOJ) and multiple sclerosis (anti-myelin / axon).
- a third possible mechanism is an anti-inflammatory action of red blood cells coated with anti-A and / or anti-B immunoglobulins, due to the inhibition induced during their phagocytosis of pro-inflammatory cytokine secretion by activated macrophages.
- This mechanism applies to all autoimmune pathologies for which the effector cells expressing Fc receptors, in particular CD16, are activated and maintain a pathogenic inflammatory state in the patient, which is observed in a large number of autoimmune pathologies. immune.
- An immunomodulation phenomenon is also possible. Indeed, a fourth possible mechanism is based on the immunomodulatory action of red blood cells coated with anti-A and / or anti-B immunoglobulins, which by limiting the cell destruction, allow the induction of a negative signal and thus a decrease of cross-link secretion of autoantibodies between BCR and FcgRIIb of B-cell via autoantibody and antigen expressed on the surface of the target cell.
- This mechanism applies to all autoimmune pathologies for which a pathogenic autoantibody is demonstrated such as ITP, insulin autoimmune syndrome (IAS) or Hirata disease (anti-insulin), optical neuromyelitis (anti-AQP4) , Grave's disease, pemphigus, multiple sclerosis (anti-myelin / axon), Sydenham chorea (anti-neuronal protein), Sjögren, Pemphigus vulgaris (anti-desmoglein 3).
- a fifth mechanism is the induction of anti-inflammatory cytokines such as IL1-RA by immune system cells, epithelial cells and adipocytes induced by erythrocytes coated with anti-A and / or anti-B immunoglobulins.
- This mechanism is particularly applicable in inflammatory diseases such as rheumatoid arthritis or for example Muckle-Wells syndrome and Schnitzler syndrome.
- the anti-A and / or anti-B immunoglobulins will directly bind to the red blood cells of patients with blood group A, B or AB and thus induce the lysis of supernumerary red blood cells.
- antibody or “immunoglobulin” is meant a molecule comprising at least one binding domain to a given antigen and a constant domain comprising a Fc fragment capable of binding to FcR receptors.
- polyclonal human immunoglobulin is meant a composition of human immunoglobulins directed against a number of distinct antigens, and comprising, for each recognized antigen, a plurality of distinct immunoglobulins capable of recognizing said antigen, generally at several distinct epitopes.
- Such polyclonal human immunoglobulins are generally purified from the plasma of one or preferably more than one donor (this is referred to as a pool of donors). Therapeutic normal human immunoglobulins are thus purified from plasma pools of generally at least 1000 donors.
- anti-A polyclonal human immunoglobulin or "anti-A immunoglobulin” is meant polyclonal human immunoglobulins recognizing blood group A antigens.
- Bood group A antigens or “A antigens” are characterized by the presence of a trisaccharide comprising an N-acetylgalactosamine (abbreviated herein as “GalNAc”) linked to a galactose (abbreviated herein as “Gaal”), itself bound to a fucose (abbreviated herein as “ Fuc "), according to the following sequence: GalNAcal -3 (Fuca1 -2) Gal.
- GalNAc N-acetylgalactosamine
- Fuc fucose
- This trisaccharide may itself be attached by its central galactose to other sugars, the number and assembly of which varies according to the type of antigen A, as shown in Table 1 below for type A antigens. 1 to 4, and the presence or absence as well as the nature of a Lewis antigen.
- Table 1 Structure of different types of antigen of blood group A.
- GalNAc N-acetylgalactosamine
- Fuc fucose
- Gal galactose
- GlcNAc N-acetylglucosamine
- Glc glucose
- R support (oligosaccharide, glycoprotein, glycolipid). The group A trisaccharide is indicated in bold.
- anti-B polyclonal human immunoglobulin or "anti-B immunoglobulin” is meant polyclonal human immunoglobulins recognizing blood group B antigens.
- Bood group B antigens or “B antigens” are characterized by the presence of a trisaccharide comprising a first galactose linked to a second galactose, itself linked to a fucose, according to the following sequence: Galal - 3 (Fuca1 -2) Gal.
- This trisaccharide can itself be attached by its central galactose to other sugars, the number and the assembly of which varies according to the type of antigen B, as indicated in Table 2 below for type B antigens. 1 to 4, and the presence or absence as well as the nature of a Lewis antigen.
- Table 2 Structure of different types of antigen of blood group B.
- Fraction of human plasma enriched in polyclonal human immunoglobulins means any fraction of human plasma that can be obtained by fractionation of human plasma and the percentage by weight of polyclonal immunoglobulins relative to the total proteins of the fraction is greater than to that of human plasma. Such fractions are advantageously obtained by fractionation of plasma pools of at least 1000 donors.
- They may in particular include any part or subpart of the plasma which has been the subject of one or more purification steps and in particular, the supernatant of cryoprecipitated plasma, plasma cryoprecipitate (delivered or not in suspension), the fractions I at V obtained by ethanolic fractionation (according to the method of Cohn or Kistler & Nitschmann), the supernatant and the precipitate obtained after precipitation with caprylic acid and / or caprylate, the filtrates, or any fraction enriched with immunoglobulins (eluates of chromatographies and / or non-adsorbed fractions) by chromatographic separation, as described in particular in WO99 / 64462 and WO02 / 092632, and more particularly in WO02 / 092632.
- oligosaccharide representing blood group A antigens is meant any oligosaccharide comprising the trisaccharide characteristic of blood group A antigens as defined above.
- GalNAcal -3 Fuca1 -2) Gal.
- Such an oligosaccharide may further comprise other sugars present in the blood group A antigens defined above.
- such an oligosaccharide may also be chosen from tetrasaccharides, pentasaccharides and hexasaccharides derived from the group A, type 1, 2, 3 or 4 antigens described above and comprising the characteristic trisaccharide GalNAcal -3 (Fuca1 -2) Gal:
- Type 1 GalNAcal -3 (Fuca1 -2) Galp1 -3GlcNAc,
- Type 3 or 4 GalNAcal -3 (Fuca1-2) Gai i -3GalNAc
- Type 1 GalNAcal -3 (Fuca1 -2) Galp1 -3GlcNAc p1 -3Gal,
- Type 2 GalNAcal -3 (Fuca1 -2) Gal 1 -4GlcNAc p1 -3Gal,
- Type 3 GalNAcal -3 (Fuca1 -2) Gal 1 -3GalNAc a1 -3Gal,
- Type 4 GalNAcal -3 (Fuca1 -2) Gal 1 -3GalNAc p1 -3Gal,
- Type 1 GalNAcal -3 (Fuca1 -2) Gal1 -3GlcNAc p1 -3GalB1 -4Glc
- Type 2 GalNAcal -3 (Fuca1 -2) Gal1 -4GlcNAc p1 -3GalB1 -4Glc
- o Type 3 GalNAcal -3 (Fuca1 -2) Gal 1 -3GalNAc has 1-3GalB1 -4GlcNAc
- Type 4 GalNAcal -3 (Fuca1 -2) Galp1 -3GalNAc i-3Gala1 -4Gal.
- the oligosaccharide may also comprise repeats of the characteristic GalNAcal -3 (Fuca1 -2) Gal trisaccharide, or tetrasaccharides, pentasaccharides and hexasaccharides derived from the type 1, 2, 3 or 4 Group A antigens described above.
- the specific ligand for immunoglobulins recognizing antigens of blood group A is the characteristic trisaccharide GalNAcal -3 (Fuca1-2) Gal.
- oligosaccharide representing antigens of blood group B is meant any oligosaccharide comprising the trisaccharide characteristic of antigens of blood group B as defined above. : Galal -3 (Fuca1 -2) Gal. Such an oligosaccharide may further comprise other sugars present in the blood group B antigens defined above.
- such an oligosaccharide may also be chosen from tetrasaccharides, pentasaccharides and hexasaccharides derived from group B, type 1, 2, 3 or 4 antigens described above and comprising the characteristic trisaccharide Galal -3 (Fuca1 -2) Gal:
- Type 3 Galal-3 (Fuca1 -2) Gal 1 -3GalNAc has 1-3GalB1 -4GlcNAc
- o Type 4 Galal-3 (Fuca1-2) Gal 1 -3GalNAc i-3Gala1 -4Gal.
- the oligosaccharide may also comprise repeats of the characteristic Galal-3 (Fuca1-2) Gal trisaccharide, or tetrasaccharides, pentasaccharides, and hexasaccharides derived from the type 1, 2, 3, or 4 B-group antigens described above.
- the specific ligand of immunoglobulins recognizing antigens of blood group B is the characteristic trisaccharide Galal -3 (Fuca1 -2) Gal.
- a reference to "a" specific ligand of anti-A or anti-B polyclonal human immunoglobulins includes the possibility of using either a single type of ligand specific for anti-A or anti-B polyclonal human immunoglobulins (that is to say that all the ligands grafted on the support have the same chemical structure), or several different types of ligands (that is to say of different chemical structure) specific (s) polyclonal human immunoglobulins anti -A or anti-B.
- each ligand of given chemical structure that can be used is necessarily grafted several times on the support, so that the polyclonal human anti-A or anti-B immunoglobulins can be retained by the support.
- One skilled in the art knows which ligand density should be used to allow adsorption of anti-A or anti-B polyclonal human immunoglobulins onto the support.
- autoimmune disease is meant any disease resulting from a dysfunction of the immune system that attacks the normal constituents of the body, or “auto-antigens”.
- Autoimmune diseases may be organ or system specific and include, in particular, autoimmune peripheral thrombocytopenia (and in particular idiopathic thrombocytopenic purpura (ITP)), Birdshot retinochoroiditis, Guillain-Barré syndrome, multifocal motor neuropathy (NMM).
- ITP idiopathic thrombocytopenic purpura
- NMM multifocal motor neuropathy
- PIDC Chronic inflammatory demyelinating polyradiculoneuropathies
- Kawasaki disease Graves' disease (hyperthyroidism), Hashimoto chronic thyroiditis (hypothyroidism), systemic lupus erythematosus (SLE), Goodpasture's syndrome, pemphigus (especially Pemphigus vulgaris (anti-desmoglein 3)), myasthenia gravis, diabetes insulin resistance, autoimmune haemolytic anemia, rheumatoid arthritis, scleroderma, polymyositis, dermatomyositis, Biermer's anemia, Sjsgren, glomerulonephritis, Wegener's disease, Horton's disease, polyarteritis nodosa, Churg and Strauss, Still's disease, atrophic polychondritis, Behçet's disease, multiple sclerosis (MS, anti-myelin / axon), s
- Thrombocytopenia or "thrombocytopenia” means a decrease in the number of blood platelets below the threshold of 150,000 platelets per mm 3 or a 50% decrease from the reference level of a subject. Thrombocytopenia is called “severe” if the number of platelets falls below the threshold of 100,000 platelets per mm 3 .
- autoimmune peripheral thrombocytopenia thrombocytopenia related to immunological destruction of platelets. This destruction implies generally B-cell synthesis of the subject of immunoglobulins directed against platelet-expressed antigens, whether natural platelet antigens or infectious antigens expressed on platelets during infection. The platelets, coated with immunoglobulins, are then destroyed by the effector cells of the immune system, and in particular by the macrophages.
- Autoimmune peripheral thrombocytopenia includes:
- IDP idiopathic thrombocytopenic purpura
- This autoimmune disease is characterized by the production of antiplatelet immunoglobulins (autoantibodies) in normally healthy subjects who do not take any medication.
- the immunological origin is asserted by the presence of a large amount of immunoglobulins (autoantibodies) on the platelet surface (see Cines et al., N Engl J Med 2002 Mar 28, 346 (13): 995-1008).
- the mechanism is similar to that of the ITP, but the causal infection is perfectly identified, the immunoglobulins binding to platelets due to their expression of an infectious antigen (see in particular Winiarski J et al., Arch Dis Child 1990 Jan; 1): 137-9 in the case of chickenpox, and Kelton et al J Clin Invest, 1983 Apr, 71 (4): 832-6 in the case of malaria).
- thrombocytopenic purpura The origin of this thrombocytopenic purpura is related to a reaction to a drug. Many drugs are capable of causing this type of thrombocytopenic purpura (see, in particular, Aster et al., N Engl J Med 2007 Aug 9; 357 (6): 580-7).
- Neonatal thrombocytopenic purpura ⁇ Neonatal thrombocytopenic purpura.
- This thrombocytopenic purpura is related either to a transplacental passage of chronic idiopathic thrombocytopenic purpura antibodies or to fetal-maternal incompatibility leading to the formation of anti-HPA (Human Platelet Antigen) antibodies (see Peterson et al., Br. Haematol 2013 Apr; 161 (1): 3-14).
- Polycythemia refers to an abnormal increase in the total volume of red blood cells in the blood. Polycythemia is therefore an excess of red blood cells, which makes the blood more viscous and can cause vascular disorders.
- polyglobulias there are:
- primary polycythemia due to an exacerbated functioning of the bone marrow that produces red blood cells, usually caused by bone marrow disease such as polycythemia vera, also called polycythemia essential, and
- polycythemia secondary to hypoxia or inappropriate secretion and / or injection of erythropoietin.
- treatment is meant a clinical or biochemical improvement of the patient's pathology.
- thrombocytopenia this can be seen in particular by an increase in the number of platelets after treatment compared to the number of platelets before treatment.
- polycythemia this can be seen in particular by a decrease in the number of red blood cells after treatment compared to the number of red blood cells before treatment.
- ком ⁇ онент with another therapeutic agent is meant the administration of the anti-A and / or anti-B polyclonal human immunoglobulin composition described herein with one or more other therapeutic agent (s), in particular with one or more drugs useful in the treatment of autoimmune disease and / or polycythemia, simultaneously or sequentially.
- “simultaneous administration” is meant both the administration in the form of a single pharmaceutical formulation associating the anti-A and / or anti-B polyclonal human immunoglobulin composition described herein and one or more other agent (s) ( s) Therapeutic (s), that separate administration of at least two separate pharmaceutical formulations containing one of the polyclonal human anti-A and / or anti-B immunoglobulin composition described herein and the other (s) formulation (s) containing the other therapeutic agent (s), at the same time or at a very short interval (maximum 1 hour).
- sequential administration is meant the separate administration of at least two separate pharmaceutical formulations containing one of the anti-A and / or anti-B polyclonal human immunoglobulin compositions described herein and the one or more formulation (s) containing the other therapeutic agent (s) more than one hour apart.
- the present invention relates to a composition
- a composition comprising polyclonal human immunoglobulins, characterized in that at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, advantageously at least 85% at least 86%. %, at least 87%, more preferably at least 88%, at least 89%, still more preferably at least 90%, at least 91%, at least 92% at least 93%, at least 94%, or at least 95% %, at least 96%, at least 97%, at least 98%, or at least 99% by weight of the polyclonal human immunoglobulins present in the composition are polyclonal human anti-A and / or anti-B immunoglobulins, for its use as a medicine.
- the invention also relates to a composition
- a composition comprising polyclonal human immunoglobulins, characterized in that at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, advantageously at least 85% at least 86%, at least 87%, more preferably at least 88%, at least 89%, still more preferably at least 90%, at least 91%, at least 92% at least 93%, at least 94% or at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by weight of the polyclonal human immunoglobulins present in the composition are anti-A and / or anti-B polyclonal human immunoglobulins for use as a medicament in the treatment of autoimmune disease and / or in the treatment of polyglobulia.
- the invention also relates to the use of a composition comprising polyclonal human immunoglobulins, characterized in that at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, advantageously at least less 85% at least 86%, at least 87%, more preferably at least 88%, at least 89%, even more preferably at least 90%, at least 91%, at least 92% at least 93%, at least 94% %, or even at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by weight of the polyclonal human immunoglobulins present in the composition are anti-A and / or anti-polyclonal human immunoglobulins -B for the preparation of a medicament, in particular for the treatment of autoimmune diseases (in particular idiopathic thrombocytopenic purpura (ITP)) and / or the treatment of polyglobulia.
- autoimmune diseases in particular idiopathic thrombocytopenic purpur
- the invention also relates to a method of treating autoimmune diseases (especially idiopathic thrombocytopenic purpura (ITP)) and / or polyglobuli in a subject in need, comprising administering to said subject an effective amount of a composition comprising polyclonal human immunoglobulins, characterized in that at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, preferably at least 85% at least 86%, at least 87% more preferably at least 88%, at least 89%, still more preferably at least 90%, at least 91%, at least 92% at least 93%, at least 94%, or at least 95%, at least 96% at least 97%, at least 98%, or at least 99% by weight of the polyclonal human immunoglobulins present in the composition are polyclonal human anti-A and / or anti-B immunoglobulins.
- the composition comprises both anti-A polyclonal human immunoglobulins and anti-B polyclonal human immunoglobulins, and the ratio by weight anti-A polyclonal human immunoglobulins on anti-B polyclonal human immunoglobulins (anti- A / anti-B) is between 1/10 and 10/1.
- the composition comprising both anti-A polyclonal human immunoglobulins and anti-B polyclonal human immunoglobulins is enriched in anti-A polyclonal human immunoglobulins, and therefore has a weight ratio of anti-A polyclonal human immunoglobulins.
- anti-B (anti-A / anti-B) polyclonal human immunoglobulins ranging from 2/1 to 10/1.
- the composition comprising both anti-A polyclonal human immunoglobulins and anti-B polyclonal human immunoglobulins is enriched in anti-B polyclonal human immunoglobulins, and therefore has a weight ratio of polyclonal anti-human immunoglobulins to A on anti-B (anti-A / anti-B) polyclonal human immunoglobulins comprised between 1/10 and 1/2.
- the composition comprising both anti-A polyclonal human immunoglobulins and anti-B polyclonal human immunoglobulins is balanced in both types of immunoglobulins, and thus has a weight ratio of polyclonal anti-human immunoglobulins to A on anti-B (anti-A / anti-B) polyclonal human immunoglobulins of between 3/10 and 7/10, advantageously between 4/10 and 6/10.
- the composition enriched in anti-A polyclonal human immunoglobulins according to the invention may have an anti-A activity enriched by a factor of at least 4, advantageously at least 5. at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least minus 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 125, at least 150 at least 175, at least 200, at least 400, at least 400, at least 500, at least 500, at least 400, at least 400, at least minus 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 4000, at least 5000, at least 6000, at least 7000, at least 8000, at least 9000, or at least 10000 in relation to a reference Im lyophil
- the composition enriched in anti-B polyclonal human immunoglobulins according to the invention may have an anti-B activity enriched by a factor of at least 4, advantageously at least 5. at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least minus 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 125, at least 150 at least 175, at least 200, at least 400, at least 400, at least 500, at least 500, at least 400, at least 400, at least minus 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 4000, at least 5000, at least 6000, at least 7000, at least 8000, at least 9000, at least 10000, at least 11000 , at least 12000
- the composition may comprise both anti-A polyclonal human immunoglobulins and anti-B polyclonal human immunoglobulins and has a ratio (anti-A activity / anti-activity).
- -B between 1/10 and 10/1, in particular between 1/9 and 9/1, between 1/8 and 8/1, between 1/7 and 7/1, between 1/6 and 6/1, between 1/5 and 5/1, between 1/4 and 4/1, between 1/3 and 3/1, even between 1/2 and 2/1 or between 0.6 and 1, 5.
- the ratio (anti-A activity / anti-B activity) and the ratio (anti-B activity / anti-A activity) are calculated on the basis of anti-A and anti-B activity results obtained in tests performed in accordance with parallel, with the same method of activity assay (in particular one of those described below, and in particular the method of flow cytometry described here) and expressed in arbitrary units with respect to the same reference standard (standard EDQM ref Y0001688 or freeze-dried human normal immunoglobulin drug).
- the weight percentage of the anti-A and / or anti-B polyclonal human immunoglobulins among total polyclonal human immunoglobulins of a composition comprising purified polyclonal human immunoglobulins can be measured by purifying the composition by affinity chromatography on a graft-donated column. ligands specific for anti-A and / or anti-B polyclonal human immunoglobulins, and relating the weight of immunoglobulins adsorbed on the column and the weight of total immunoglobulins.
- composition is not purified in immunoglobulins, a preliminary step of purification of total immunoglobulins then makes it possible to measure the percentage by weight of anti-A and / or anti-B polyclonal human immunoglobulins among the total polyclonal human immunoglobulins.
- compositions for therapeutic use according to the invention are preferably purified, and the polyclonal human immunoglobulins advantageously represent at least 85%, advantageously at least 86%, at least 87%, more advantageously at least 88%, at least 89%, still more preferably at least 90%, at least 91%, at least 92% at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by weight of the total proteins of the composition.
- compositions for therapeutic use according to the invention may comprise polyclonal human immunoglobulins of a single isotype (IgG, IgM, IgA, IgD, IgE, advantageously IgG or IgM, preferably IgG) or several isotypes.
- the polyclonal human immunoglobulins present in the compositions for therapeutic use according to the invention are predominantly (at least 90%, advantageously at least 91%, at least 92%, at least 93%, at least least 94%, more preferably at least 95%, at least 96%, at least 97%, still more preferably at least 98%, at least 99% by weight) IgG.
- compositions for therapeutic use according to the invention are advantageously enriched in IgG2 subclass immunoglobulins compared to normal human immunoglobulin concentrates.
- the IgG compositions for therapeutic use according to the invention are advantageously characterized in that at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%.
- immunoglobulins of subclass IgG2 advantageously measured by nephelemetry and / or by spectrography and or by subclass ELISA kit (ie by nephelemetry, by spectrography, by subclass ELISA kit, or by several of these methods, for example by nephelemetry and by spectrography, or by each of these three methods) .
- the IgG compositions according to the invention advantageously have a weight ratio of IgG 2 / IgG 1 of at least 0.8, at least 0.9, advantageously at least 1, at least 1.1, at least 1, 2, at least 1, 3, at least 1, 4, at least 1, 5, at least 1, 6, at least 1, 7, at least 1, 8, at least 1, 9 or at least 2 at least 2.5, at least 3, at least 3.1, at least 3.2, at least 3.3, at least 3.4, at least 3.5, at least 3.6, at least 3 , 7, at least 3.8, at least 3.9, or even at least 4, advantageously measured by nephelemetry and / or by spectrography and / or by subclass ELISA assay kit (ie by nephelometry, by spectrography, by kit Subclass ELISA, or by several of these methods, for example by nephelemetry and spectrography, or by each of these three methods).
- the polyclonal human immunoglobulins present in the compositions for therapeutic use according to the invention are predominantly (at least 90%, advantageously at least 91%, at least 92%, at least 93%, at least 94%, more preferably at least 95%, at least 96%, at least 97%, still more preferably at least 98%, at least 99% by weight) IgM.
- compositions according to the invention are purified and are advantageously concentrated.
- the compositions according to the invention are concentrated according to any technique known to those skilled in the art, for example by using an ultrafiltration membrane, a centrifugation, a dialysis, or several of these steps.
- the concentrated compositions according to the invention exhibit an indirect Coombs test result (described below) greater than 1/64, advantageously greater than 1/128, greater than 1/256, greater than 1/512, greater than 1/1024, greater than 1/2048, even greater than 1/4096.
- An indirect Coombs test result greater than 1 / N means that the result of the indirect Coombs test is negative at a dilution of the sample at 1 / N.
- compositions according to the invention which are concentrated exhibit a result with the direct agglutination method (described below) greater than 1/64, advantageously greater than 1/128, greater than 1/256, greater than 1 / 512, greater than 1/1024, greater than 1/2048, even greater than 1/4096.
- Direct agglutination test result greater than 1 / N means that the result with the direct agglutination method is negative at a dilution of the sample at 1 / N.
- compositions according to the invention concentrate have a concentration of anti-A and / or anti-B polyclonal human immunoglobulins greater than 1 g / L, greater than 1.5 g / L, greater than 2 g / L, greater than 5 g / L, greater than 10 g / L, greater than 1 5 g / L, greater than 20 g / L, or even greater than 50 g / L.
- the rationale for the therapeutic effectiveness of the compositions for therapeutic use according to the invention for the treatment of autoimmune diseases relies in particular on saturating the macrophages with red blood cells coated with anti-human polyclonal immunoglobulins. A and / or anti-B administered, thus preventing the destruction of platelets by these same macrophages.
- the Fc receptors of the macrophages are then saturated with red blood cells coated with anti-A and / or anti-B polyclonal human immunoglobulins, preventing the binding of platelets coated with other antibodies. Without binding to macrophages, platelets are not destroyed.
- the rational of the therapeutic effectiveness is based on the fixation of anti-A and / or anti-B polyclonal human immunoglobulins administered directly to the red blood cells, thus causing their lysis.
- compositions for therapeutic use according to the invention are advantageously intended for blood group A patients (erythrocytes carrying A antigens recognized by the anti-A), B polyclonal human immunoglobulins (B-labeled antigen-recognized red blood cells). polyclonal human immunoglobulins anti-B) or AB (red blood cells carrying antigens A and B recognized by anti-A and anti-B polyclonal human immunoglobulins).
- compositions for therapeutic use according to the invention for the treatment of autoimmune diseases is also based on:
- complement proteins by erythrocytes coated with anti-A and / or anti-B immunoglobulins, reducing the complement-dependent activity of pathogenic autoantibodies to treat autoimmune pathologies for which the role of the complement is deleterious for the patient such as optical neuromyelitis (anti-AQP4) and multiple sclerosis (anti-myelin / axon).
- anti-AQP4 optical neuromyelitis
- anti-myelin / axon multiple sclerosis
- red blood cells coated with anti-A and / or anti-B immunoglobulins due to the inhibition induced during their phagocytosis of the secretion of pro-inflammatory cytokines by activated macrophages for treating autoimmune pathologies for which the effector cells expressing Fc receptors, in particular CD16, are activated and maintain a pathogenic inflammatory state in the patient.
- cytokines such as IL1 -RA
- immune system cells epithelial cells and adipocytes induced by erythrocytes coated with anti-A and / or anti-B immunoglobulins for treating inflammatory pathologies.
- compositions for therapeutic use according to the invention comprise both anti-A and anti-B polyclonal human immunoglobulins, they are advantageously intended for patients of blood group A, B or AB, and in particular of blood group AB.
- compositions for therapeutic use according to the invention can be used in the treatment of autoimmune diseases.
- compositions for therapeutic use according to the invention can in particular be used in the treatment of peripheral autoimmune thrombocytopenia (involving immunological destruction of platelets, in particular PTI), Birdshot retinochoroiditis, Guillain-Barré syndrome, multifocal motor neuropathy.
- peripheral autoimmune thrombocytopenia involving immunological destruction of platelets, in particular PTI
- Birdshot retinochoroiditis involving immunological destruction of platelets, in particular PTI
- Guillain-Barré syndrome multifocal motor neuropathy.
- NMM chronic inflammatory demyelinating polyradiculoneuropathies
- PIDC chronic inflammatory demyelinating polyradiculoneuropathies
- Kawasaki disease Graves' disease (hyperthyroidism), chronic thyroiditis of Hashimoto (hypothyroidism), systemic lupus erythematosus (SLE), Goodpasture's syndrome , pemphigus (including Pemphigus vulgaris (anti-desmoglein 3)), myasthenia gravis, diabetes insulin resistance, autoimmune haemolytic anemia, rheumatoid arthritis, scleroderma, polymyositis, dermatomyositis , Biermer's anemia, Sjsgren's disease, Glomerulonephritis, Wegener's disease, Horton's disease, periarteritis nodosa, Churg and Strauss syndrome, Still's disease, atrophic polychondritis, Behçet
- composition according to the invention for treating autoimmune diseases.
- autoimmune diseases for which the role of complement is deleterious for the patient for example optical neuromyelitis (anti-AQP4) and multiple sclerosis (anti-myelin / axon) can be treated by the composition according to the invention by the mechanism of consumption of complement proteins by erythrocytes coated with anti-A and / or anti-B immunoglobulins.
- optical neuromyelitis anti-AQP4
- multiple sclerosis anti-myelin / axon
- the autoimmune diseases for which the effector cells expressing Fc receptors, in particular CD16, are activated and maintain a pathogenic inflammatory state in the patient can be treated with the composition according to the invention by virtue of the anti-inflammatory action of red blood cells. coated with anti-A and / or anti-B immunoglobulins.
- autoimmune diseases for which a pathogenic autoantibody is demonstrated such as ITP, insulin autoimmune syndrome (IAS) or Hirata disease (anti-insulin), optic neuromyelitis (anti-AQP4), Grave's disease, pemphigus, multiple sclerosis (anti-myelin / axon), Sydenham chorea (neuronal antiprotein), Sjögren, Pemphigus vulgaris (anti-desmoglein 3) can be treated with the composition according to the invention by virtue of the immunomodulatory action of red blood cells. coated with anti-A and / or anti-B immunoglobulins.
- inflammatory type autoimmune diseases such as rheumatoid arthritis or for example Muckle-Wells syndrome and Schnitzler syndrome can be treated by the composition according to the invention by virtue of the mechanism for inducing anti-inflammatory cytokines as IL1 -RA by the cells of the immune system.
- compositions for therapeutic use according to the invention can be used in the treatment of autoimmune peripheral thrombocytopenia, involving an immunological destruction of platelets.
- the rational of the therapeutic efficacy of the compositions for therapeutic use according to the invention is based in particular on the fact of saturating the macrophages by red blood cells coated with anti-A and / or anti-polyclonal human immunoglobulins. -B administered, thus preventing the destruction of platelets by these same macrophages.
- the mechanisms of consumption of complement proteins by red blood cells coated with anti-A and / or anti-B immunoglobulins, anti-inflammatory action of erythrocytes coated with anti-A and / or anti-B immunoglobulins, immunomodulatory action of red blood cells coated with anti-A and / or anti-B immunoglobulins, and induction of anti-inflammatory cytokines such as IL1 -RA by the cells of the immune system, also make it possible to prevent the destruction of platelets.
- compositions for therapeutic use according to the invention are especially advantageously used in the treatment of idiopathic thrombocytopenic purpura (ITP), infectious thrombocytopenic purpura, immunoallergic drug thrombocytopenic purpura, or neonatal thrombocytopenic purpura, and in particular in the treatment of thrombocytopenic purpura.
- ITP idiopathic thrombocytopenic purpura
- infectious thrombocytopenic purpura infectious thrombocytopenic purpura
- immunoallergic drug thrombocytopenic purpura or neonatal thrombocytopenic purpura
- neonatal thrombocytopenic purpura idiopathic iopathic (PTI).
- compositions for therapeutic use according to the invention can be used in the treatment of polyglobulia.
- compositions for therapeutic use according to the invention can be used in the treatment of polyglobulia, involving an increase in the amount of red blood cells.
- the rational of the therapeutic efficacy is based on the fixation of polyclonal human anti-A and / or anti-B immunoglobulins administered directly to red blood cells, thus causing their lysis.
- compositions for therapeutic use according to the invention are especially advantageously used in the treatment of primary polycythemia, in particular in polycythemia vera, also called essential polycythemia, and / or in the treatment of secondary polycythemia due to hypoxia or secretion and / or or inappropriate injection of erythropoietin. Dosage and therapeutic administration
- compositions for therapeutic use according to the invention at an appropriate dosage.
- compositions according to the invention necessarily involves the destruction of a number of red blood cells (hemolysis), and it is therefore appropriate not to overdose the compositions for therapeutic use according to the invention, so as to avoid too much haemolysis, which is also harmful for the subject treated.
- hemolysis red blood cells
- the quantities of anti-A and anti-B immunoglobulins present in therapeutic polyclonal human immunoglobulin concentrates are limited to maximum values by the health authorities.
- polyclonal human immunoglobulin therapeutic concentrates are used as substitution treatment in primary or secondary immunodeficiencies with defective antibody production, maximum risk of hemolysis should be avoided.
- the dose of anti-A and / or anti-B immunoglobulins administered to a patient suffering from polycythemia and / or autoimmune disease, and in particular autoimmune peripheral thrombocytopenia (in particular particular of ITP), should preferably be between 20 and 100 ⁇ g / kg of body weight, advantageously between 25 and 90 ⁇ g / kg of body weight, between 30 and 80 ⁇ g / kg of body weight, between 35 and 70 ⁇ g / kg of body weight, kg of body weight, between 40 and 60 ⁇ g / kg of body weight, between 45 and 55 ⁇ g / kg of body weight, and in particular of approximately 50 ⁇ g / kg of body weight.
- the doses are advantageously adapted to avoid severe hemolysis in the patient that could lead to serious and / or deleterious side effects.
- composition for therapeutic use according to the invention is intended to bind to red blood cells, it is advantageously administered intravenously.
- the composition for therapeutic use according to the invention is administered enterally, parenterally, locally and cutaneo-mucosa.
- the rate of administration may be from about 1 to 5 ml (in particular 1 to 4 ml, 1 to 3 ml, or about 2 ml) of a composition comprising 150 mg / l of anti-A and / or anti-immunoglobulin. -B every 15 to 60 seconds.
- the composition for therapeutic use according to the invention may also be administered in combination with another therapeutic agent chosen from the medicaments useful in the treatment of an autoimmune disease and / or a polycythemia.
- the frequency of administration of the composition for therapeutic use according to the invention is adapted according to the platelet rate to be reached and / or or maintain in the patient.
- compositions for therapeutic use according to the invention can be obtained from more or less purified fractions of human plasma comprising polyclonal immunoglobulins by various purification methods, and in particular by a process comprising the following methods: following steps: a) adsorption of a batch of human plasma or a fraction of human plasma enriched in polyclonal human immunoglobulins on a support grafted with a ligand specific for anti-A polyclonal human immunoglobulins and / or a ligand specific for human immunoglobulins polyclonal anti-B, b) setting aside the unadsorbed fraction for possible future use, and
- compositions for therapeutic use according to the invention is based on a specific adsorption step of anti-A and / or anti-B polyclonal human immunoglobulins on a substrate grafted with a specific ligand of these immunoglobulins, which are then eluted.
- a specific adsorption step of anti-A and / or anti-B polyclonal human immunoglobulins on a substrate grafted with a specific ligand of these immunoglobulins which are then eluted.
- the process for the preparation of the compositions for therapeutic use according to the invention can be integrated into a more general method for the purification of therapeutic normal human immunoglobulins (recovery of fractions which have been eliminated up to now) and can therefore be implemented on a fraction of pre-purified polyclonal human immunoglobulins.
- This prepurified polyclonal human immunoglobulin fraction advantageously contains a polyclonal human immunoglobulin content of at least 80%, advantageously at least 81%, at least 82%, more preferably at least 83%, at least 84%, even more preferably at at least 85%, at least 86%, at least 87% at least 88%, at least 89% or at least 90%, at least 91%, or at least 92% by weight of the total protein of the fraction.
- the fraction of prepurified polyclonal human immunoglobulins may in particular have been obtained by chromatographic separation, in particular according to the purification methods of polyclonal human immunoglobulins described in WO99 / 64462 and WO02 / 092632, and more particularly in WO02 / 092,632.
- the prepurified polyclonal human immunoglobulin fraction is obtained by pre-purification by a step of precipitation of lipid contaminants from a blood plasma or an IgG-enriched blood plasma fraction, and a single chromatography step on an anion exchange resin carrier carried out at alkaline pH, with a selective elution of IgG in one step by an appropriate buffer at a pH of between 4 and 7.
- the prepurification by a step of precipitation of lipid contaminants consists of a step precipitation with caprylic acid.
- the prepurified polyclonal human immunoglobulin fraction may also have undergone a biological safety step (viral elimination and / or inactivation). viral, in particular by a solvent-detergent treatment), a concentration step (in particular by ultrafiltration), and / or a sterilizing filtration step.
- the support may be any suitable support capable of being chosen by those skilled in the art for adsorbing polyclonal human anti-A and / or anti-B immunoglobulins. .
- Such a support used in step a) is advantageously in the form:
- a polymeric membrane grafted with the ligand or ligands of interest.
- the support may thus in particular be in the form of particles grafted by the ligand or ligands of interest.
- the particles are advantageously of spherical or oblong shape, they may especially be balls. These particles generally have an average size of about 0.1 ⁇ to about 1000 ⁇ , preferably about 20 to about 50 ⁇ , more preferably about 50 to about 200 ⁇ , more preferably about 70 ⁇ . ⁇ at about 120 ⁇ in diameter. They may consist of polymer or inorganic materials (such as silica or glass for example).
- the particles are porous.
- the polymer may be natural or non-natural (synthetic or semisynthetic), organic or inorganic (preferably the polymer will be organic), crosslinked or uncrosslinked (preferably the polymer will be crosslinked).
- the polymer is a crosslinked organic polymer.
- the polymer may especially be chosen from cellulose and its derivatives, agarose, dextran, polyacrylates, polystyrene, polyacrylamide, polymethacrylamide, copolymers of styrene and divinylbenzene, or mixtures of these polymers.
- the polymer is cellulose, and the particles are preferably porous cellulose beads. More preferably, it is crosslinked cellulose.
- the support may also be in the form of a polymeric membrane, the membrane being grafted with the ligand or ligands of interest.
- the polymer of the membrane may be selected from the polymers mentioned above for the polymer particles.
- the particles are advantageously incorporated in a gel or a resin, which is used as a matrix of an affinity chromatography column.
- the polymeric membrane can be included in an affinity chromatography column.
- the human plasma batch or the human plasma fraction enriched in polyclonal human immunoglobulins are then adsorbed on the affinity chromatography column, and the adsorbed fraction is eluted and recovered.
- an affinity chromatography column is not essential, and other modes of adsorption, dissociation and harvesting may be used.
- the specific ligand for anti-A polyclonal human immunoglobulins may be any appropriate molecule known to those skilled in the art and binding to anti-A polyclonal human immunoglobulins such as as defined above and not binding to other immunoglobulins.
- Such a ligand is advantageously chosen from oligosaccharides representative of group A, type 1, 2, 3 and 4 antigens, and in particular from the following oligosaccharides:
- Trisaccharide GalNAca1-3 (Fuca1-2) Gal;
- Type 1 GalNAca1-3 (Fuca1-2) Galp1 -3GlcNAc p1-3Gal,
- Type 4 GalNAca1-3 (Fuca1-2) Gal 1 -3GalNAc p1-3Gal,
- Type 1 GalNAca1-3 (Fuca1-2) Gal 1 -3GlcNAc 1 ⁇ 3Gal61 -4Glc
- Type 2 GalNAca1-3 (Fuca1-2) Gal 1 -4GlcNAc p1-3GalB1 -4Glc
- Type 3 GalNAca1- 3 (Fuca1-2) Gal 1 -3GalNAc has 1-3GalB1 -4GlcNAc
- Type 4 GalNAca1-3 (Fuca1-2) Gal61 -3GalNAc 61-3Gala1-4Gal.
- the specific ligand for anti-B polyclonal human immunoglobulins may be any appropriate molecule known to those skilled in the art and binding to anti-B polyclonal human immunoglobulins such as as defined above and not binding to other immunoglobulins.
- Such a ligand is advantageously chosen from oligosaccharides representative of group B antigens of type 1, 2, 3 and 4, and in particular from the following oligosaccharides:
- Trisaccharide Gala1-3 (Fuca1-2) Gal;
- Pentasaccharides o Type 1: Gala1 -3 (Fuca1 -2) Galp1 -3GlcNAc p1 -3Gal,
- Type 3 Gala1 -3 (Fuca1 -2) G1 -3GalNAc a1 -3GalB1 -4GlcNAc
- o Type 4 Gala1 -3 (Fuca1-2) Gal61 -3GalNAc 61 -3Gala1 -4Gal.
- the support may be grafted with a ligand specific for anti-A polyclonal human immunoglobulins and / or with a ligand specific for anti-B polyclonal human immunoglobulins.
- the support is grafted only by a ligand specific for anti-A polyclonal human immunoglobulins.
- the support is grafted only by a specific ligand of anti-B polyclonal human immunoglobulins.
- the support is grafted with a specific ligand specific for anti-A polyclonal human immunoglobulins and with a ligand specific for anti-B polyclonal human immunoglobulins.
- a mixture of supports grafted with a ligand specific for anti-A polyclonal human immunoglobulins and supports grafted with a ligand specific for anti-B polyclonal human immunoglobulins in respective proportions generally between 25/75 ( v / v) and 75/25 (v / v), and in particular 50/50 (v / v).
- particles grafted with the ligand (s) of interest when particles grafted with the ligand (s) of interest are used, it is possible to use a mixture of particles grafted with a ligand specific for anti-A polyclonal human immunoglobulins and particles grafted with a ligand specific for anti-human polyclonal immunoglobulins. -B to prepare a gel and fill an affinity chromatography column.
- the particles grafted with a specific ligand of the anti-A polyclonal human immunoglobulins and the particles grafted with a specific ligand of anti-B polyclonal human immunoglobulins are mixed in respective proportions generally between 25/75 (v / v).
- v / v 75/25 (v / v), and especially 50/50 (v / v).
- a support comprising particles grafted with both a ligand specific for anti-A polyclonal human immunoglobulins and with a ligand specific for anti-B polyclonal human immunoglobulins.
- a mixture it is also possible to use a mixture:
- Particles grafted at the same time by a ligand specific for anti-A polyclonal human immunoglobulins and by a ligand specific for anti-B polyclonal human immunoglobulins and Particles grafted with a ligand specific for anti-A polyclonal human immunoglobulins and / or particles grafted with a ligand specific for anti-B polyclonal human immunoglobulins.
- the ligand of interest is advantageously grafted on the polymer particles or on the polymeric membrane by means of a spacer, which makes it possible to reduce the steric hindrance and make the trisaccharide characteristic of antigens A or B more accessible to immunoglobulins likely to adsorb on the support.
- Such a spacer may be any appropriate group known to those skilled in the art to allow the grafting of the ligand of interest and therefore in particular of oligosaccharides on a support of interest, in particular the polymers described above.
- the spacer typically comprises at least one atom of C, O, N, or S, and will most often comprise at least one of the following chemical functions: ether (-), thioether (-S-), amino (-NH-) , carboxy - (- COO- or -OCO-), amide (-CONH- or -HNOC-).
- the spacer may in particular have a structure chosen from:
- each of X1 and X2 is independently selected from 0, S, and NH; and each of Ra, Rb, Rc, and Rd is independently selected from H, OH, and methyl.
- R1 is a C4-C6 alkyl group
- R2 is a C3-C8 alkyl group
- said spacer is bonded by its amine function (in bold) above) to the support.
- R1 is a linear or branched, preferably linear, C4-C6 alkyl group.
- R 1 is a C 5 alkyl group.
- R2 is a linear or branched, preferably linear, C3-C8 alkyl group.
- R2 is a C3 alkyl group.
- the ligands (which are preferably trisaccharides as described above) are grafted to the particles or to the membrane by a spacer according to the formula: (particle / membrane) -NH-C5Hio-CO-NH -C3H6- (ligand).
- the coupling between the particle or the membrane and the spacer, on the one hand, and the coupling between the spacer and the specific ligand of the anti-A polyclonal human immunoglobulins or the specific ligand of the anti-B polyclonal human immunoglobulins can be realized. by any appropriate chemical synthesis protocol known to those skilled in the art.
- the particle or membrane may carry an -NH-R1 -COOH arm.
- it is ⁇ -aminocaproic acid (where R 1 is a pentyl group).
- the particle can then be activated using bifunctional reagents such as epichlorohydrin, epibromohydrin, dibromo- and dichloropropanol, dibromobutane, ethylene glycol diglycidylether, butanediol diglycidylether, divinylsulfone, and the like. allyl glycidyl ether, and allyl bromide.
- the bifunctional reagent is capable of reacting with both the particles / membrane and the NH-R1 -COOH arm.
- the heterofunctional allyl compounds such as allyl bromide, are preferred bifunctional reagents and make it possible to obtain an activated matrix.
- the ligands representing the blood group A and / or B antigens are then immobilized on the activated particle / membrane carrying the -NH-R1 -COOH arm via a linker group -NH-R2-, where R2 is a C3 alkyl group. -C8, linear or branched, preferably linear.
- the COOH function of the -NH-R1 -COOH arm carried by the particle / membrane is reacted with the NH 2 function of the NH 2 -R 2 -ligosaccharide ligand, by the use of a type of condensation agent.
- substrates grafted with a ligand specific for anti-A polyclonal human immunoglobulins which may be used in the context of the invention are the following: Glycosorb ABO A (Sepharose matrix on which is grafted the trisaccharide characteristic of the antigen A, Glycorex Transplantation AB, Lund, Sweden), Allotran A (trisaccharide characteristic of matrix A antigen) FF Sepharose by polyacrylamide, Lectinity Corp), HyperCel IsoA (crosslinked cellulose particles grafted with the trisaccharide characteristic of antigen A, Pall).
- Glycosorb ABO A Sepharose matrix on which is grafted the trisaccharide characteristic of the antigen A, Glycorex Transplantation AB, Lund, Sweden
- Allotran A trisaccharide characteristic of matrix A antigen
- FF Sepharose by polyacrylamide Lectinity Corp
- HyperCel IsoA crosslinked cellulose particles grafted with the
- substrates grafted with a ligand specific for anti-B polyclonal human immunoglobulins which may be used in the context of the invention are the following: Glycosorb ABO B (Sepharose matrix on which is grafted the trisaccharide characteristic of antigen B, Glycorex Transplantation AB, Lund, Sweden), Allotran B (trisaccharide characteristic of poly-Fr-substituted Sepharose FF matrix-bound antigen, Lectinity Corp), HyperCel IsoB (trisaccharide-grafted crosslinked cellulose particles characteristic of B-antigen) , Pall).
- Glycosorb ABO B Sepharose matrix on which is grafted the trisaccharide characteristic of antigen B, Glycorex Transplantation AB, Lund, Sweden
- Allotran B trisaccharide characteristic of poly-Fr-substituted Sepharose FF matrix-bound antigen, Lectinity Corp
- a substrate ligated with a specific ligand of anti-A polyclonal human immunoglobulins and with a ligand specific for anti-B polyclonal human immunoglobulins a mixture of a polyclonal human immunoglobulin-specific ligand-specific support will generally be used.
- anti-A as described above and a specific ligand-grafted anti-B polyclonal human immunoglobulin support as described above.
- particles grafted with the ligand (s) of interest when particles grafted with the ligand (s) of interest are used, it is possible to use a mixture of particles grafted with a ligand specific for anti-A polyclonal human immunoglobulins and particles grafted with a ligand specific for anti-human polyclonal immunoglobulins. -B to prepare a gel and fill an affinity chromatography column. It is also possible to use particles grafted with both a ligand specific for anti-A polyclonal human immunoglobulins and a ligand specific for anti-B polyclonal human immunoglobulins to prepare a gel and fill an affinity chromatography column. It is also possible to use a mixture:
- Particles grafted with a ligand specific for anti-A polyclonal human immunoglobulins and / or particles grafted with a ligand specific for anti-B polyclonal human immunoglobulins Particles grafted with a ligand specific for anti-A polyclonal human immunoglobulins and / or particles grafted with a ligand specific for anti-B polyclonal human immunoglobulins.
- the batch of human plasma or the fraction of human plasma enriched in polyclonal human immunoglobulins is adsorbed in step a) on the chromatography column.
- the batch of human plasma or the fraction of human plasma enriched in polyclonal human immunoglobulins on the column may in particular be implemented.
- the unadsorbed fraction is advantageously recovered for other subsequent uses.
- the adsorbed fraction is then dissociated and recovered using one or more washes of the column by one or more appropriate elution buffers.
- An acidic elution buffer for example a glycine-HCl buffer, pH between 2 and 4
- a basic elution buffer for example a glycine-NaOH solution, pH between 10 and 12
- composition thus obtained may also be subjected to one or more subsequent optional steps, such as: a step of neutralization of the composition (pH adjustment between 3 and 9, preferably between 4 and 5), one or more additional purification steps a concentration step (for example by ultrafiltration), at least one inactivation step (solvent-detergent treatment for example) or viral elimination (nanofiltration for example), or a combination of several of these steps.
- a step of neutralization of the composition pH adjustment between 3 and 9, preferably between 4 and 5
- additional purification steps a concentration step (for example by ultrafiltration), at least one inactivation step (solvent-detergent treatment for example) or viral elimination (nanofiltration for example), or a combination of several of these steps.
- the method as described above makes it possible to obtain a polyclonal human immunoglobulin composition which recognizes at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, advantageously at least 85%. % at least 86%, at least 87%, more preferably at least 88%, at least 89%, still more preferably at least 90%, at least 91%, at least 92% at least 93%, at least 94%, or at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by weight of the polyclonal human immunoglobulins present in the composition of the blood group A and B antigens.
- the purified composition then comprises a mixture of human immunoglobulins.
- polyclonal anti-A and anti-B polyclonal human immunoglobulins are polyclonal anti-A and anti-B polyclonal human immunoglobulins.
- the proportion of polyclonal human anti-A immunoglobulins and anti-B polyclonal human immunoglobulins depends on the initial donor population. In fact, differences in the percentage of distribution of the different blood groups exist according to the donor populations. These variations can therefore be found in the anti-A polyclonal human immunoglobulin compositions and / or anti-B polyclonal human immunoglobulins according to the invention.
- step a) When the support used in step a) is grafted solely by a specific ligand of anti-A polyclonal human immunoglobulins, anti-A polyclonal human immunoglobulins are retained, and the composition obtained then comprises anti-A polyclonal human immunoglobulins.
- the support used in step a) is grafted solely by a specific ligand of anti-B polyclonal human immunoglobulins, anti-B polyclonal human immunoglobulins are retained, and the composition obtained then comprises polyclonal human immunoglobulins anti-B B.
- the invention furthermore relates to a composition obtainable by one of the preparation methods described above, for its use as a medicament, in particular in the treatment of autoimmune diseases (in particular autoimmune peripheral thrombocytopenia) and / or polycythemia (primitive or secondary).
- a first composition of polyclonal human immunoglobulins according to the invention, enriched with anti-A and anti-B polyclonal human immunoglobulins was prepared.
- a purified polyclonal human immunoglobulin composition was prepared from a plasma pool according to the method described in WO02 / 092632.
- This purified polyclonal human immunoglobulin composition was then adsorbed onto a gel-filled 1 mL affinity chromatography column comprising a mixture of porous crosslinked cellulose beads grafted with the trisaccharide characteristic of group A antigens (column A). and porous crosslinked cellulose beads grafted with the trisaccharide characteristic of Group B antigens (column B), in respective proportions of 50/50.
- the charge was 1.8 kg of purified polyclonal human immunoglobulin composition per liter of gel.
- the contact time was set at 2 minutes.
- the unadsorbed fraction is recovered for further processing to prepare a polyclonal human immunoglobulin therapeutic concentrate free of anti-A and anti-B polyclonal human immunoglobulins.
- fraction of interest in the context of the present invention is then obtained by assembling two elution fractions:
- composition was then analyzed by the usual technologies to determine the concentration of IgG, IgA and IgM, the levels of polymers, dimers, monomers and immunoglobulin fragments.
- the anti-A and anti-B activity of the composition was also analyzed by the method described in WO2007 / 077365 and compared to that of a freeze-dried normal human immunoglobulin.
- IgG 9.20 g / L (Subclasses: IgG1: 65%, IgG2: 30%, IgG3: 3%, IgG4: 2%)
- the assembly fraction of the two successive elutions with an acid buffer and then with a basic buffer has the following characteristics:
- the anti-A activity and the anti-B activity are expressed in arbitrary units relative to a freeze-dried normal human immunoglobulin, a product considered as a reference level set to 1.
- the freeze-dried normal human immunoglobulin therefore exhibits for the A and anti-B a negative result in the Coombs direct dilution test 1/64 as required by the Regulatory authorities.
- the composition obtained by the method according to the invention has an anti-A activity and an anti-B activity approximately 600 times greater than the polyvalent normal human immunoglobulins of freeze-dried normal human immunoglobulin (therapeutic concentrate of polyclonal human immunoglobulins).
- mice are further injected with AB group human red blood cells and anti-polyclonal immunoglobulins.
- -A and anti-B see Figure 1.
- the C57BL / 6J test mice (groups 2-5) were injected with ⁇ g / 20g body weight of anti-CD41 antibody which depletes the platelets (MW Reg 30 clone, # 3214555, BD Biosciences, San Jose, CA, USA), diluted in 100 ⁇ l / 20 g body weight of PBS (# 14190-094 Invitrogen, France) (the amount and volume of injection were adapted according to the weight of the mice) intraperitoneally (ip) days 1 to 5.
- mice (group 1) were injected with saline (0.09% NaCl). Preparation and administration of IVIG
- IVIG (LFB) was diluted in PBS1X at the working concentration of 100 mg / mL (1 g / kg).
- Group AB + human red blood cells in isotonic glucose NaCl solution were diluted 1: 4 in 0.09% NaCl (300 ⁇ l + 100 ⁇ l) and administered to 3-5 groups intravenously at day 2; 3h after the blood collection for hematological analysis (corresponding to 8 hours after the injection of anti-CD41 at day 2).
- the human anti-A / anti-B antibodies were prepared at the required dose (injection of 100 ⁇ l of anti-A anti-B at 7.5 mg / kg in 0.1 M glycine at pH 6) and administered in group 4 by intraperitoneal route at day 2, 30 minutes after injection of human red blood cells (corresponding to 8:30 after the injection of anti-CD41 at day 2).
- Blood 50 ⁇ was collected daily by retroperitoneal puncture under anesthesia with 3% isoflurane (DDG9623, # 11 K10A33, Baxter, France), in tubes (containing ethylenediaminetetraacetic acid (EDTA), vacutainer, Becton Dickinson ) for all animals included in the study, 1 h before (only at day 1) and 5 h after the injection of anti-CD41.
- DDG9623 ethylenediaminetetraacetic acid
- vacutainer containing ethylenediaminetetraacetic acid (EDTA), vacutainer, Becton Dickinson ) for all animals included in the study, 1 h before (only at day 1) and 5 h after the injection of anti-CD41.
- Blood was homogenized and blood cell composition determined using a 5-part differential hematological analyzer (MS9-5 Melet Schloesing Laboratories).
- Platelet depletion which reflects the extent of thrombocytopenic purpura, was analyzed with a hematological analyzer.
- Winiarski J Platelet antigens in varicella associated thrombocytopenia. Arch Dis Child. 1990 Jan; 65 (1): 137-9.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1554117A FR3035789A1 (fr) | 2015-05-07 | 2015-05-07 | Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies |
PCT/EP2016/060157 WO2016177870A1 (fr) | 2015-05-07 | 2016-05-06 | Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3291834A1 true EP3291834A1 (fr) | 2018-03-14 |
Family
ID=53758393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16725051.3A Withdrawn EP3291834A1 (fr) | 2015-05-07 | 2016-05-06 | Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies |
Country Status (4)
Country | Link |
---|---|
US (1) | US20180142036A1 (fr) |
EP (1) | EP3291834A1 (fr) |
FR (1) | FR3035789A1 (fr) |
WO (1) | WO2016177870A1 (fr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE298889T1 (de) * | 1999-10-08 | 2005-07-15 | Vi Technologies Inc | Von isoagglutinin befreite blutzusammensetzungen und verfahren zu ihrer herstellung |
-
2015
- 2015-05-07 FR FR1554117A patent/FR3035789A1/fr not_active Withdrawn
-
2016
- 2016-05-06 WO PCT/EP2016/060157 patent/WO2016177870A1/fr active Application Filing
- 2016-05-06 EP EP16725051.3A patent/EP3291834A1/fr not_active Withdrawn
- 2016-05-06 US US15/570,511 patent/US20180142036A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
FR3035789A1 (fr) | 2016-11-11 |
US20180142036A1 (en) | 2018-05-24 |
WO2016177870A1 (fr) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3016729B1 (fr) | Matrice de chromatographie d'affinité | |
RU2749732C2 (ru) | Препараты антител | |
US5487890A (en) | Mammalian primate erythrocyte bound heteropolymerized monoclonal antibodies and methods of use thereof | |
HUT65139A (en) | Process for separating biomolecules by using linear polymers | |
SK288128B6 (sk) | Process for purifying immunoglobulin G (IgG), liquid immunoglobulin product and use thereof for the preparation of a medicament | |
JP2703764B2 (ja) | 補体成分C5aに対するモノクローナル抗体 | |
EP3752215A1 (fr) | Dispositifs extracorporels et méthodes de traitement de maladies associées au facteur du complément | |
FR3008097A1 (fr) | Matrice de chromatographie d'affinite | |
WO2019115773A1 (fr) | Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc | |
JPH0213371A (ja) | ハイブリドーマ細胞系、モノクローナル抗体およびそのキメラ | |
KR20110128271A (ko) | Abo식 혈액형과 관련한 모-태아 간 부적합에 의해 야기된 신생아 황달 치료용 항-a 및 항-b가 대폭 감소된 면역 글로불린 g(면역 글로불린 g) 농축물의 용도 | |
FR3008098A1 (fr) | Matrice de chromatographie d'affinite a densite de ligands reduite | |
WO2016177870A1 (fr) | Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b pour son utilisation dans le traitement des maladies autoimmunes ou des polyglobulies | |
JPS601136A (ja) | 血液製剤中の不適合反応原因物質不活化法 | |
Stahl et al. | Warm autoimmune hemolytic anemia is an IgM–IgG immune complex disease | |
Morell | Various immunoglobulin preparations for intravenous use | |
EP3266870A1 (fr) | Conjugué et son utilisation | |
EP3291904A1 (fr) | Composition enrichie en immunoglobulines polyclonales anti-a et/ou anti-b | |
JP4249028B2 (ja) | 蛋白質の活性化方法 | |
WO2019129848A1 (fr) | Procédé de purification d'anticorps à partir de lait brut | |
Foo et al. | Chemical treatment of anti‐D results in improved efficacy for the inhibition of Fcγ receptor–mediated phagocytosis | |
CN103880957A (zh) | 抗cd20抗原的抗体l1h1及其应用 | |
WO2018226493A1 (fr) | Anticorps humain purifié se liant au motif microbien de liaison à l'héparine et son procédé d'utilisation | |
WO2005094880A1 (fr) | Methode servant a traiter des maladies auto-immunes au moyen d'anticorps | |
AU2013322614A1 (en) | Test for hemolytic potential of pharmaceutical products and formulations for risk minimization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20171207 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/00 20060101ALI20190410BHEP Ipc: C07K 16/06 20060101ALI20190410BHEP Ipc: A61K 39/395 20060101AFI20190410BHEP Ipc: A61P 7/02 20060101ALI20190410BHEP Ipc: A61K 38/36 20060101ALI20190410BHEP |
|
INTG | Intention to grant announced |
Effective date: 20190503 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190914 |